Cytopia to be acquired by YM BioSciences

Cytopia to be acquired by YM BioSciences

Pharmaceutical manufacturer Cytopia (ASX:CYT) has agreed to be acquired by Toronto-based YM BioSciences.

Under the arrangement, Cytopia investors will be offered 1 YM share for every 11.7 shares they own. This represents a share price offer of $0.17 per Cytopia share – a 58% premium.

The combined companies will develop and conduct clinical trials for cancer treatments.

YM Biosciences has a market capitalization of around C$87 million ($92.7 million) and cash and cash equivalents of around C$41 million. It last closed at C$1.49 on the Tronto stock exchange.

Join the CIO Australia group on LinkedIn. The group is open to CIOs, IT Directors, COOs, CTOs and senior IT managers.

Join the newsletter!


Sign up to gain exclusive access to email subscriptions, event invitations, competitions, giveaways, and much more.

Membership is free, and your security and privacy remain protected. View our privacy policy before signing up.

Error: Please check your email address.

Tags Mergers and acquisitionsCytopiapharmaceuticals

Show Comments